Sign In
Last checked at 
14 Aug 2025 18:01
Abingdon Health plc
("Abingdon Health", the "Group" or the "Company")
PDMR Shareholding
York, U.K. 14 August 2025: Abingdon Health plc (AIM: ABDX), a leading international developer, manufacturer and regulatory services provider for rapid tests and med-tech, was informed on 14 August 2025 that Chris Yates, Group Chief Commercial Officer and President, Abingdon Health USA Inc, has sold 800,000 ordinary shares of 0.025 pence each in the Company ("Ordinary Shares").
Consequently, Mr Yates' total beneficial interest in the Company is now 7,088,844 Ordinary Shares, representing approximately 3.66% of the Company's issued share capital.
Commenting, Chris Yates, said: "The decision to sell a limited proportion of my shares does not diminish my enthusiasm for the Company and confidence in the continued strong revenue growth we expect to deliver. I remain a significant shareholder and excited about my role overseeing the successful development of the US business and commercial activities globally."
Enquiries:
Abingdon Health plc | www.abingdonhealth.com/investors/ | ||
Chris Hand, Executive Chairman
| Via Walbrook PR | ||
Tom Hayes, CFO
| |||
Zeus (Sole Broker and Nominated Adviser) | Tel: +44 (0)20 3829 5000 | ||
Antonio Bossi / Jacob Walker (Corporate Finance) | |||
Fraser Marshall (Corporate Broking)
|
| ||
Walbrook PR (Media & Investor Relations) | Tel: +44 (0)20 7933 8780 or abingdon@walbrookpr.com | ||
Paul McManus / Alice Woodings | Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654 | ||
About Abingdon Health plc
Abingdon Health Group is a leading med-tech contract service provider offering its services to an international customer base.
The Group's CDMO expertise offers lateral flow product development, regulatory support, technology transfer and manufacturing services for customers looking to develop new assays or transfer existing laboratory-based assays to a lateral flow format. Abingdon Health has the internal capabilities to take lateral flow projects, in areas such as infectious disease and clinical testing, including companion diagnostics, animal health and environmental testing, from initial concept through to routine manufacturing; from "idea to commercial success". Abingdon Analytical Ltd offers performance evaluation for lateral flow and other in vitro diagnostic assays from its Doncaster laboratory.
Abingdon's regulatory services companies, Compliance Solutions (Life Sciences) and IVDeology, provide a broad range of regulatory services to the in vitro diagnostic and wider medical device industry, to support customers in bringing products to market across a range of territories including the USA, EU and the UK. Our consultancy services range from design, implementation and maintenance of quality management systems, preparation of technical files for regulatory approvals, part-time and interim management support, auditing both internal and external, management reviews and presentations, training and mentoring.
Founded in 2008, Abingdon Health is headquartered in York, England with laboratories in Doncaster, England and laboratories and commercial offices in Madison, Wisconsin, USA.
Abingdon Health's brochure outlines the comprehensive support the Group can now provide to its international customers. For more information visit: www.abingdonhealth.com.
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM
1 | Details of the person discharging managerial responsibilities / person closely associated | ||
a) | Name | Chris Yates
| |
2 | Reason for the notification | ||
a) | Position/status | Chief Commercial Officer / President, Abingdon Health USA Inc
| |
b) | Initial notification/Amendment | Initial Notification
| |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
a) | Name | Abingdon Health plc
| |
b) | LEI | 213800XFI4WV3FBILO20
| |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
a) | Description of the financial instrument, type of instrument | Ordinary Shares of 0.025 pence each
| |
Identification code | GB00BLF79J41
| ||
b) | Nature of the transaction | Sale of Ordinary Shares
| |
c) | Price(s) and volumes(s) | Price(s) | Volume(s) |
6.231p | 800,000 | ||
d) | Aggregated information
| ||
Aggregated volume | 800,000 | ||
Price | 6.231p
| ||
e) | Date of the transaction | 14 August 2025
| |
f) | Place of the transaction | London Stock Exchange
| |
Follow the stocks
